nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—VIIth nerve paralysis—Vemurafenib—melanoma	0.0275	0.0544	CcSEcCtD
Methyldopa—VIIth nerve paralysis—Carmustine—melanoma	0.0145	0.0288	CcSEcCtD
Methyldopa—Vasculitis—Vemurafenib—melanoma	0.0115	0.0229	CcSEcCtD
Methyldopa—Isoprenaline—MAPK1—melanoma	0.00826	0.466	CrCbGaD
Methyldopa—Tenderness—Bleomycin—melanoma	0.00782	0.0155	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Vemurafenib—melanoma	0.00737	0.0146	CcSEcCtD
Methyldopa—Eosinophilia—Vemurafenib—melanoma	0.007	0.0139	CcSEcCtD
Methyldopa—Endocrine disorder—Temozolomide—melanoma	0.00695	0.0138	CcSEcCtD
Methyldopa—Liver injury—Temozolomide—melanoma	0.00684	0.0135	CcSEcCtD
Methyldopa—Foetor hepaticus—Docetaxel—melanoma	0.00675	0.0134	CcSEcCtD
Methyldopa—Amenorrhoea—Temozolomide—melanoma	0.00655	0.013	CcSEcCtD
Methyldopa—Infestation—Vemurafenib—melanoma	0.0063	0.0125	CcSEcCtD
Methyldopa—Infestation NOS—Vemurafenib—melanoma	0.0063	0.0125	CcSEcCtD
Methyldopa—Liver disorder—Docetaxel—melanoma	0.00562	0.0111	CcSEcCtD
Methyldopa—Connective tissue disorder—Vemurafenib—melanoma	0.00556	0.011	CcSEcCtD
Methyldopa—Gynaecomastia—Carmustine—melanoma	0.00533	0.0106	CcSEcCtD
Methyldopa—Cardiac disorder—Vemurafenib—melanoma	0.00525	0.0104	CcSEcCtD
Methyldopa—Angiopathy—Vemurafenib—melanoma	0.00513	0.0102	CcSEcCtD
Methyldopa—Mediastinal disorder—Vemurafenib—melanoma	0.0051	0.0101	CcSEcCtD
Methyldopa—Nasal congestion—Temozolomide—melanoma	0.00459	0.00909	CcSEcCtD
Methyldopa—Amenorrhoea—Docetaxel—melanoma	0.00436	0.00863	CcSEcCtD
Methyldopa—Liver function test abnormal—Dactinomycin—melanoma	0.00427	0.00845	CcSEcCtD
Methyldopa—Myalgia—Vemurafenib—melanoma	0.00419	0.0083	CcSEcCtD
Methyldopa—Arthralgia—Vemurafenib—melanoma	0.00419	0.0083	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00416	0.00825	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Dactinomycin—melanoma	0.00416	0.00824	CcSEcCtD
Methyldopa—Pancytopenia—Bleomycin—melanoma	0.00407	0.00805	CcSEcCtD
Methyldopa—Infection—Vemurafenib—melanoma	0.00399	0.00791	CcSEcCtD
Methyldopa—Liver function test abnormal—Carmustine—melanoma	0.00399	0.00791	CcSEcCtD
Methyldopa—Nervous system disorder—Vemurafenib—melanoma	0.00394	0.00781	CcSEcCtD
Methyldopa—Skin disorder—Vemurafenib—melanoma	0.0039	0.00773	CcSEcCtD
Methyldopa—Mesalazine—PPARG—melanoma	0.00384	0.216	CrCbGaD
Methyldopa—Hepatocellular injury—Docetaxel—melanoma	0.00383	0.00758	CcSEcCtD
Methyldopa—Pancytopenia—Dactinomycin—melanoma	0.00379	0.00751	CcSEcCtD
Methyldopa—Breast disorder—Temozolomide—melanoma	0.00378	0.00748	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Temozolomide—melanoma	0.00376	0.00745	CcSEcCtD
Methyldopa—Colitis—Docetaxel—melanoma	0.00368	0.00728	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00366	0.00725	CcSEcCtD
Methyldopa—Abdominal distension—Temozolomide—melanoma	0.00364	0.0072	CcSEcCtD
Methyldopa—Pancytopenia—Carmustine—melanoma	0.00355	0.00703	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Vemurafenib—melanoma	0.00347	0.00687	CcSEcCtD
Methyldopa—Constipation—Vemurafenib—melanoma	0.00344	0.00681	CcSEcCtD
Methyldopa—Pancytopenia—Temozolomide—melanoma	0.00343	0.00679	CcSEcCtD
Methyldopa—Lightheadedness—Docetaxel—melanoma	0.00343	0.00678	CcSEcCtD
Methyldopa—Erectile dysfunction—Temozolomide—melanoma	0.00333	0.00659	CcSEcCtD
Methyldopa—Agranulocytosis—Dactinomycin—melanoma	0.00332	0.00658	CcSEcCtD
Methyldopa—Weight increased—Temozolomide—melanoma	0.00329	0.00651	CcSEcCtD
Methyldopa—Infestation NOS—Temozolomide—melanoma	0.00322	0.00638	CcSEcCtD
Methyldopa—Infestation—Temozolomide—melanoma	0.00322	0.00638	CcSEcCtD
Methyldopa—Hepatitis—Dactinomycin—melanoma	0.0032	0.00633	CcSEcCtD
Methyldopa—Body temperature increased—Vemurafenib—melanoma	0.00318	0.00629	CcSEcCtD
Methyldopa—Cardiac failure congestive—Docetaxel—melanoma	0.00307	0.00607	CcSEcCtD
Methyldopa—Hepatobiliary disease—Temozolomide—melanoma	0.00305	0.00603	CcSEcCtD
Methyldopa—Hypersensitivity—Vemurafenib—melanoma	0.00296	0.00586	CcSEcCtD
Methyldopa—Connective tissue disorder—Carmustine—melanoma	0.00294	0.00582	CcSEcCtD
Methyldopa—Hepatitis—Temozolomide—melanoma	0.00289	0.00573	CcSEcCtD
Methyldopa—Asthenia—Vemurafenib—melanoma	0.00288	0.00571	CcSEcCtD
Methyldopa—Connective tissue disorder—Temozolomide—melanoma	0.00284	0.00563	CcSEcCtD
Methyldopa—Diarrhoea—Vemurafenib—melanoma	0.00275	0.00545	CcSEcCtD
Methyldopa—Cardiac disorder—Temozolomide—melanoma	0.00268	0.00531	CcSEcCtD
Methyldopa—Leukopenia—Bleomycin—melanoma	0.00267	0.00529	CcSEcCtD
Methyldopa—Dizziness—Vemurafenib—melanoma	0.00266	0.00526	CcSEcCtD
Methyldopa—Angiopathy—Temozolomide—melanoma	0.00262	0.00519	CcSEcCtD
Methyldopa—Mental disorder—Carmustine—melanoma	0.00262	0.00519	CcSEcCtD
Methyldopa—Mediastinal disorder—Temozolomide—melanoma	0.00261	0.00516	CcSEcCtD
Methyldopa—Liver function test abnormal—Docetaxel—melanoma	0.00257	0.00508	CcSEcCtD
Methyldopa—Vomiting—Vemurafenib—melanoma	0.00256	0.00506	CcSEcCtD
Methyldopa—Myalgia—Bleomycin—melanoma	0.00254	0.00503	CcSEcCtD
Methyldopa—Orthostatic hypotension—Docetaxel—melanoma	0.00254	0.00503	CcSEcCtD
Methyldopa—Rash—Vemurafenib—melanoma	0.00253	0.00502	CcSEcCtD
Methyldopa—Mental disorder—Temozolomide—melanoma	0.00253	0.00502	CcSEcCtD
Methyldopa—Dermatitis—Vemurafenib—melanoma	0.00253	0.00501	CcSEcCtD
Methyldopa—Headache—Vemurafenib—melanoma	0.00252	0.00499	CcSEcCtD
Methyldopa—Breast disorder—Docetaxel—melanoma	0.00251	0.00497	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Docetaxel—melanoma	0.0025	0.00496	CcSEcCtD
Methyldopa—Leukopenia—Dactinomycin—melanoma	0.00249	0.00493	CcSEcCtD
Methyldopa—Oedema—Bleomycin—melanoma	0.00244	0.00482	CcSEcCtD
Methyldopa—Infection—Bleomycin—melanoma	0.00242	0.00479	CcSEcCtD
Methyldopa—Nausea—Vemurafenib—melanoma	0.00239	0.00473	CcSEcCtD
Methyldopa—Thrombocytopenia—Bleomycin—melanoma	0.00238	0.00472	CcSEcCtD
Methyldopa—Myalgia—Dactinomycin—melanoma	0.00237	0.00469	CcSEcCtD
Methyldopa—Angina pectoris—Docetaxel—melanoma	0.00234	0.00463	CcSEcCtD
Methyldopa—Leukopenia—Carmustine—melanoma	0.00233	0.00462	CcSEcCtD
Methyldopa—Pancytopenia—Docetaxel—melanoma	0.00228	0.00452	CcSEcCtD
Methyldopa—Oedema—Dactinomycin—melanoma	0.00227	0.0045	CcSEcCtD
Methyldopa—Infection—Dactinomycin—melanoma	0.00226	0.00447	CcSEcCtD
Methyldopa—Leukopenia—Temozolomide—melanoma	0.00225	0.00446	CcSEcCtD
Methyldopa—Thrombocytopenia—Dactinomycin—melanoma	0.00222	0.0044	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Bleomycin—melanoma	0.00222	0.00439	CcSEcCtD
Methyldopa—Myalgia—Carmustine—melanoma	0.00222	0.00439	CcSEcCtD
Methyldopa—Paraesthesia—Bleomycin—melanoma	0.00219	0.00433	CcSEcCtD
Methyldopa—Weight increased—Docetaxel—melanoma	0.00219	0.00433	CcSEcCtD
Methyldopa—Arthralgia—Temozolomide—melanoma	0.00214	0.00424	CcSEcCtD
Methyldopa—Myalgia—Temozolomide—melanoma	0.00214	0.00424	CcSEcCtD
Methyldopa—Infestation—Docetaxel—melanoma	0.00214	0.00424	CcSEcCtD
Methyldopa—Infestation NOS—Docetaxel—melanoma	0.00214	0.00424	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00213	0.00421	CcSEcCtD
Methyldopa—Oedema—Carmustine—melanoma	0.00213	0.00421	CcSEcCtD
Methyldopa—Infection—Carmustine—melanoma	0.00211	0.00418	CcSEcCtD
Methyldopa—Jaundice—Docetaxel—melanoma	0.00209	0.00413	CcSEcCtD
Methyldopa—Thrombocytopenia—Carmustine—melanoma	0.00208	0.00412	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00207	0.0041	CcSEcCtD
Methyldopa—Aminosalicylic Acid—PTGS2—melanoma	0.00206	0.116	CrCbGaD
Methyldopa—Oedema—Temozolomide—melanoma	0.00205	0.00407	CcSEcCtD
Methyldopa—Infection—Temozolomide—melanoma	0.00204	0.00404	CcSEcCtD
Methyldopa—Hepatobiliary disease—Docetaxel—melanoma	0.00203	0.00401	CcSEcCtD
Methyldopa—Nervous system disorder—Temozolomide—melanoma	0.00201	0.00399	CcSEcCtD
Methyldopa—Thrombocytopenia—Temozolomide—melanoma	0.00201	0.00398	CcSEcCtD
Methyldopa—Agranulocytosis—Docetaxel—melanoma	0.002	0.00396	CcSEcCtD
Methyldopa—Skin disorder—Temozolomide—melanoma	0.002	0.00395	CcSEcCtD
Methyldopa—Epinephrine—TNF—melanoma	0.00196	0.111	CrCbGaD
Methyldopa—Musculoskeletal discomfort—Carmustine—melanoma	0.00194	0.00384	CcSEcCtD
Methyldopa—Body temperature increased—Bleomycin—melanoma	0.00193	0.00381	CcSEcCtD
Methyldopa—Hepatitis—Docetaxel—melanoma	0.00192	0.00381	CcSEcCtD
Methyldopa—Paraesthesia—Carmustine—melanoma	0.00191	0.00378	CcSEcCtD
Methyldopa—Connective tissue disorder—Docetaxel—melanoma	0.00189	0.00374	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Temozolomide—melanoma	0.00187	0.00371	CcSEcCtD
Methyldopa—Paraesthesia—Temozolomide—melanoma	0.00184	0.00365	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Carmustine—melanoma	0.00184	0.00363	CcSEcCtD
Methyldopa—Constipation—Carmustine—melanoma	0.00182	0.0036	CcSEcCtD
Methyldopa—Body temperature increased—Dactinomycin—melanoma	0.0018	0.00356	CcSEcCtD
Methyldopa—Hypersensitivity—Bleomycin—melanoma	0.00179	0.00355	CcSEcCtD
Methyldopa—Cardiac disorder—Docetaxel—melanoma	0.00178	0.00353	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Temozolomide—melanoma	0.00177	0.00351	CcSEcCtD
Methyldopa—Constipation—Temozolomide—melanoma	0.00176	0.00348	CcSEcCtD
Methyldopa—Asthenia—Bleomycin—melanoma	0.00175	0.00346	CcSEcCtD
Methyldopa—Angiopathy—Docetaxel—melanoma	0.00174	0.00345	CcSEcCtD
Methyldopa—Mediastinal disorder—Docetaxel—melanoma	0.00173	0.00343	CcSEcCtD
Methyldopa—Mental disorder—Docetaxel—melanoma	0.00168	0.00334	CcSEcCtD
Methyldopa—Body temperature increased—Carmustine—melanoma	0.00168	0.00333	CcSEcCtD
Methyldopa—Hypersensitivity—Dactinomycin—melanoma	0.00167	0.00331	CcSEcCtD
Methyldopa—Asthenia—Dactinomycin—melanoma	0.00163	0.00323	CcSEcCtD
Methyldopa—Body temperature increased—Temozolomide—melanoma	0.00162	0.00322	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—melanoma	0.00162	0.0913	CrCbGaD
Methyldopa—Hypersensitivity—Carmustine—melanoma	0.00157	0.0031	CcSEcCtD
Methyldopa—Diarrhoea—Dactinomycin—melanoma	0.00155	0.00308	CcSEcCtD
Methyldopa—Vomiting—Bleomycin—melanoma	0.00155	0.00307	CcSEcCtD
Methyldopa—Rash—Bleomycin—melanoma	0.00154	0.00304	CcSEcCtD
Methyldopa—Dermatitis—Bleomycin—melanoma	0.00153	0.00304	CcSEcCtD
Methyldopa—Asthenia—Carmustine—melanoma	0.00153	0.00302	CcSEcCtD
Methyldopa—Hypersensitivity—Temozolomide—melanoma	0.00151	0.003	CcSEcCtD
Methyldopa—Leukopenia—Docetaxel—melanoma	0.0015	0.00297	CcSEcCtD
Methyldopa—Asthenia—Temozolomide—melanoma	0.00147	0.00292	CcSEcCtD
Methyldopa—Diarrhoea—Carmustine—melanoma	0.00145	0.00288	CcSEcCtD
Methyldopa—Nausea—Bleomycin—melanoma	0.00145	0.00286	CcSEcCtD
Methyldopa—Vomiting—Dactinomycin—melanoma	0.00144	0.00286	CcSEcCtD
Methyldopa—Rash—Dactinomycin—melanoma	0.00143	0.00284	CcSEcCtD
Methyldopa—Arthralgia—Docetaxel—melanoma	0.00143	0.00282	CcSEcCtD
Methyldopa—Myalgia—Docetaxel—melanoma	0.00143	0.00282	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00142	0.0028	CcSEcCtD
Methyldopa—Dizziness—Carmustine—melanoma	0.00141	0.00278	CcSEcCtD
Methyldopa—Diarrhoea—Temozolomide—melanoma	0.00141	0.00278	CcSEcCtD
Methyldopa—Oedema—Docetaxel—melanoma	0.00137	0.00271	CcSEcCtD
Methyldopa—Dizziness—Temozolomide—melanoma	0.00136	0.00269	CcSEcCtD
Methyldopa—Infection—Docetaxel—melanoma	0.00136	0.00269	CcSEcCtD
Methyldopa—Vomiting—Carmustine—melanoma	0.00135	0.00268	CcSEcCtD
Methyldopa—Nausea—Dactinomycin—melanoma	0.00135	0.00267	CcSEcCtD
Methyldopa—Rash—Carmustine—melanoma	0.00134	0.00265	CcSEcCtD
Methyldopa—Nervous system disorder—Docetaxel—melanoma	0.00134	0.00265	CcSEcCtD
Methyldopa—Dermatitis—Carmustine—melanoma	0.00134	0.00265	CcSEcCtD
Methyldopa—Thrombocytopenia—Docetaxel—melanoma	0.00134	0.00265	CcSEcCtD
Methyldopa—Headache—Carmustine—melanoma	0.00133	0.00264	CcSEcCtD
Methyldopa—Skin disorder—Docetaxel—melanoma	0.00133	0.00263	CcSEcCtD
Methyldopa—Vomiting—Temozolomide—melanoma	0.00131	0.00259	CcSEcCtD
Methyldopa—Rash—Temozolomide—melanoma	0.0013	0.00256	CcSEcCtD
Methyldopa—Dermatitis—Temozolomide—melanoma	0.00129	0.00256	CcSEcCtD
Methyldopa—Headache—Temozolomide—melanoma	0.00129	0.00255	CcSEcCtD
Methyldopa—Nausea—Carmustine—melanoma	0.00126	0.0025	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Docetaxel—melanoma	0.00124	0.00246	CcSEcCtD
Methyldopa—Paraesthesia—Docetaxel—melanoma	0.00123	0.00243	CcSEcCtD
Methyldopa—Nausea—Temozolomide—melanoma	0.00122	0.00242	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Docetaxel—melanoma	0.00118	0.00234	CcSEcCtD
Methyldopa—Constipation—Docetaxel—melanoma	0.00117	0.00231	CcSEcCtD
Methyldopa—Body temperature increased—Docetaxel—melanoma	0.00108	0.00214	CcSEcCtD
Methyldopa—Hypersensitivity—Docetaxel—melanoma	0.00101	0.00199	CcSEcCtD
Methyldopa—Asthenia—Docetaxel—melanoma	0.00098	0.00194	CcSEcCtD
Methyldopa—Diarrhoea—Docetaxel—melanoma	0.000935	0.00185	CcSEcCtD
Methyldopa—Dizziness—Docetaxel—melanoma	0.000903	0.00179	CcSEcCtD
Methyldopa—Vomiting—Docetaxel—melanoma	0.000869	0.00172	CcSEcCtD
Methyldopa—Rash—Docetaxel—melanoma	0.000861	0.00171	CcSEcCtD
Methyldopa—Dermatitis—Docetaxel—melanoma	0.000861	0.0017	CcSEcCtD
Methyldopa—Headache—Docetaxel—melanoma	0.000856	0.00169	CcSEcCtD
Methyldopa—Nausea—Docetaxel—melanoma	0.000812	0.00161	CcSEcCtD
Methyldopa—COMT—Neuronal System—HRAS—melanoma	0.000246	0.000516	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IFNB1—melanoma	0.000245	0.000514	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP1B1—melanoma	0.000242	0.000506	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLCB4—melanoma	0.000241	0.000505	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CD—melanoma	0.00024	0.000502	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IFNA1—melanoma	0.000239	0.000501	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—RHOB—melanoma	0.000237	0.000497	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—ALB—melanoma	0.000237	0.000496	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCR7—melanoma	0.000237	0.000496	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GRM1—melanoma	0.000237	0.000496	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SYK—melanoma	0.000232	0.000487	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT3—melanoma	0.000228	0.000478	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ITGAV—melanoma	0.000228	0.000478	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIP4K2A—melanoma	0.000227	0.000475	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC6A11—melanoma	0.000227	0.000475	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ABCB1—melanoma	0.000224	0.00047	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IFNA2—melanoma	0.000223	0.000467	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTAP—melanoma	0.000221	0.000462	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ALB—melanoma	0.000216	0.000453	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCR2—melanoma	0.000216	0.000453	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RHOB—melanoma	0.000215	0.000451	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—EDN1—melanoma	0.000214	0.000449	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—RAC2—melanoma	0.000212	0.000445	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CB—melanoma	0.000209	0.000438	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ITGB1—melanoma	0.000207	0.000434	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PRKCA—melanoma	0.000206	0.000432	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ERCC2—melanoma	0.000205	0.000429	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLCB4—melanoma	0.000202	0.000423	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL1—melanoma	0.000202	0.000423	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ABCB1—melanoma	0.000199	0.000417	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PHGDH—melanoma	0.000197	0.000412	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LUM—melanoma	0.000197	0.000412	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCR2—melanoma	0.000196	0.000411	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RAC2—melanoma	0.000193	0.000404	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HPSE—melanoma	0.000193	0.000404	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IL2—melanoma	0.000192	0.000402	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCL8—melanoma	0.000191	0.000401	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—WNT5A—melanoma	0.00019	0.000398	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TRRAP—melanoma	0.00019	0.000397	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CUL3—melanoma	0.00019	0.000397	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HGF—melanoma	0.000189	0.000397	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CUBN—melanoma	0.000189	0.000397	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CSF2—melanoma	0.000187	0.000392	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKR1B10—melanoma	0.000184	0.000387	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—F2R—melanoma	0.000184	0.000385	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PRKCA—melanoma	0.000183	0.000384	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SDHD—melanoma	0.000183	0.000383	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BSG—melanoma	0.000183	0.000383	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CSPG4—melanoma	0.000183	0.000383	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ERCC2—melanoma	0.000182	0.000381	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ITGB3—melanoma	0.00018	0.000376	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PRKCA—melanoma	0.00018	0.000376	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—EDNRB—melanoma	0.000178	0.000373	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPAM—melanoma	0.000177	0.000371	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—F2RL1—melanoma	0.000172	0.000359	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GAB2—melanoma	0.000168	0.000352	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GNA11—melanoma	0.000168	0.000352	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—F2R—melanoma	0.000167	0.000349	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—RAC1—melanoma	0.000166	0.000349	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—melanoma	0.000163	0.000342	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CG—melanoma	0.000162	0.000339	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EDNRB—melanoma	0.000161	0.000338	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRM3—melanoma	0.000161	0.000338	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MMP1—melanoma	0.000161	0.000337	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CDK2—melanoma	0.000158	0.000331	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCR4—melanoma	0.000158	0.000331	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GNAQ—melanoma	0.000156	0.000327	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPARG—melanoma	0.000156	0.000327	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MAPK3—melanoma	0.000154	0.000323	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KISS1—melanoma	0.000153	0.00032	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GNA11—melanoma	0.000153	0.00032	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GAB2—melanoma	0.000153	0.00032	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000152	0.000319	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLA2G6—melanoma	0.000151	0.000315	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCR1—melanoma	0.000148	0.00031	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SKI—melanoma	0.000148	0.00031	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—FN1—melanoma	0.000147	0.000308	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MAPK1—melanoma	0.000147	0.000308	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MC1R—melanoma	0.000146	0.000306	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS2—melanoma	0.000145	0.000304	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT3—melanoma	0.000144	0.000302	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CG—melanoma	0.000143	0.000301	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCR4—melanoma	0.000143	0.0003	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CD—melanoma	0.000142	0.000298	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GNAQ—melanoma	0.000142	0.000297	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CG—melanoma	0.000141	0.000295	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALB—melanoma	0.00014	0.000294	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRM1—melanoma	0.00014	0.000293	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR7—melanoma	0.00014	0.000293	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—EGF—melanoma	0.000139	0.000291	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPARG—melanoma	0.000138	0.00029	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SUFU—melanoma	0.000136	0.000286	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—VCAN—melanoma	0.000135	0.000283	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT3—melanoma	0.000131	0.000274	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IGF1—melanoma	0.000129	0.00027	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—melanoma	0.000127	0.000267	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RHOB—melanoma	0.000127	0.000267	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BCL2L11—melanoma	0.000127	0.000267	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CD—melanoma	0.000126	0.000264	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALB—melanoma	0.000124	0.000261	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CB—melanoma	0.000124	0.000259	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CD—melanoma	0.000124	0.000259	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—melanoma	0.000123	0.000257	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HDAC6—melanoma	0.000122	0.000256	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ALB—melanoma	0.000122	0.000256	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—EDN1—melanoma	0.000121	0.000254	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CSF2—melanoma	0.000118	0.000248	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCR2—melanoma	0.000116	0.000243	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL8—melanoma	0.000116	0.000243	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP17A1—melanoma	0.000114	0.000239	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RAC2—melanoma	0.000114	0.000239	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCA—melanoma	0.000113	0.000238	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—WNT5A—melanoma	0.000112	0.000235	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFC—melanoma	0.000112	0.000235	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EDN1—melanoma	0.00011	0.00023	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CB—melanoma	0.00011	0.00023	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—melanoma	0.000109	0.000228	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GNA11—melanoma	0.000108	0.000226	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CB—melanoma	0.000108	0.000226	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CSF2—melanoma	0.000107	0.000225	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTEN—melanoma	0.000107	0.000224	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—FASN—melanoma	0.000105	0.000221	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—RAC1—melanoma	0.000105	0.00022	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—melanoma	0.000104	0.000218	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC5A5—melanoma	0.000104	0.000217	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCA—melanoma	0.000103	0.000216	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAP2K2—melanoma	0.000101	0.000211	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GNAQ—melanoma	0.0001	0.00021	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CD44—melanoma	0.0001	0.00021	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IL2—melanoma	9.89e-05	0.000207	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—F2R—melanoma	9.85e-05	0.000206	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP1B1—melanoma	9.6e-05	0.000201	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RAC1—melanoma	9.55e-05	0.0002	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDNRB—melanoma	9.54e-05	0.0002	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTEN—melanoma	9.5e-05	0.000199	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTK2B—melanoma	9.26e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GAB2—melanoma	9.01e-05	0.000189	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNA11—melanoma	9.01e-05	0.000189	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FLT1—melanoma	8.97e-05	0.000188	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CG—melanoma	8.89e-05	0.000186	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FOXO4—melanoma	8.47e-05	0.000178	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HDAC2—melanoma	8.47e-05	0.000178	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCR4—melanoma	8.47e-05	0.000178	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—melanoma	8.41e-05	0.000176	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNAQ—melanoma	8.38e-05	0.000176	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NRAS—melanoma	8.31e-05	0.000174	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CG—melanoma	8.07e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK3—melanoma	7.95e-05	0.000167	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCB1—melanoma	7.91e-05	0.000166	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SYK—melanoma	7.87e-05	0.000165	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CD—melanoma	7.81e-05	0.000164	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT3—melanoma	7.73e-05	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NGFR—melanoma	7.73e-05	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ITGAV—melanoma	7.73e-05	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK1—melanoma	7.57e-05	0.000159	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CA—melanoma	7.55e-05	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PRKCA—melanoma	7.28e-05	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ERCC2—melanoma	7.22e-05	0.000151	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SOCS1—melanoma	7.16e-05	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KRAS—melanoma	7.15e-05	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAP2K1—melanoma	7.14e-05	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—S100B—melanoma	7.14e-05	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CD—melanoma	7.09e-05	0.000149	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB4—melanoma	6.83e-05	0.000143	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CB—melanoma	6.81e-05	0.000143	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN2B—melanoma	6.77e-05	0.000142	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CA—melanoma	6.7e-05	0.00014	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CA—melanoma	6.57e-05	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CD86—melanoma	6.55e-05	0.000137	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL8—melanoma	6.54e-05	0.000137	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDN1—melanoma	6.49e-05	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—melanoma	6.35e-05	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CSF2—melanoma	6.35e-05	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF1—melanoma	6.35e-05	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL2—melanoma	6.25e-05	0.000131	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—E2F1—melanoma	6.21e-05	0.00013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CB—melanoma	6.18e-05	0.00013	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—melanoma	6.16e-05	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFRA—melanoma	6.15e-05	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ITGB3—melanoma	6.09e-05	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCA—melanoma	6.09e-05	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HRAS—melanoma	6.08e-05	0.000127	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SPP1—melanoma	5.97e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAP2K2—melanoma	5.95e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL8—melanoma	5.94e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CG—melanoma	5.7e-05	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL2—melanoma	5.68e-05	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TERT—melanoma	5.66e-05	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RAC1—melanoma	5.64e-05	0.000118	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARG—melanoma	5.5e-05	0.000115	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—melanoma	5.47e-05	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIF1A—melanoma	5.41e-05	0.000113	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—melanoma	5.37e-05	0.000112	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KDR—melanoma	5.17e-05	0.000108	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CD—melanoma	5.01e-05	0.000105	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FN1—melanoma	4.98e-05	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALB—melanoma	4.95e-05	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH1—melanoma	4.87e-05	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CD80—melanoma	4.78e-05	0.0001	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APC—melanoma	4.77e-05	9.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CG—melanoma	4.77e-05	9.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KIT—melanoma	4.77e-05	9.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—NRAS—melanoma	4.77e-05	9.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGF—melanoma	4.71e-05	9.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAPK3—melanoma	4.56e-05	9.57e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BRAF—melanoma	4.48e-05	9.39e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CB—melanoma	4.37e-05	9.15e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1—melanoma	4.36e-05	9.15e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAPK1—melanoma	4.34e-05	9.1e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EGFR—melanoma	4.34e-05	9.1e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—melanoma	4.33e-05	9.07e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAP2K1—melanoma	4.22e-05	8.84e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CD—melanoma	4.19e-05	8.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	4.15e-05	8.7e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KRAS—melanoma	4.1e-05	8.6e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF2—melanoma	4.01e-05	8.41e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTEN—melanoma	3.77e-05	7.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	3.77e-05	7.9e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MDM2—melanoma	3.75e-05	7.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB2—melanoma	3.7e-05	7.76e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CB—melanoma	3.65e-05	7.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL8—melanoma	3.51e-05	7.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HRAS—melanoma	3.49e-05	7.31e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN1B—melanoma	3.43e-05	7.18e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—melanoma	3.39e-05	7.11e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP3—melanoma	3.36e-05	7.04e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL2—melanoma	3.35e-05	7.03e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—melanoma	3.34e-05	6.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCND1—melanoma	3.27e-05	6.85e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CTNNB1—melanoma	3.24e-05	6.79e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—melanoma	3.17e-05	6.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN1A—melanoma	3.16e-05	6.63e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTEN—melanoma	3.16e-05	6.61e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NFKB1—melanoma	3.14e-05	6.58e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—melanoma	3.08e-05	6.45e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—melanoma	2.85e-05	5.97e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT3—melanoma	2.82e-05	5.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NRAS—melanoma	2.82e-05	5.9e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK3—melanoma	2.7e-05	5.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CA—melanoma	2.66e-05	5.58e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—melanoma	2.62e-05	5.5e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK1—melanoma	2.57e-05	5.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGFR—melanoma	2.57e-05	5.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KRAS—melanoma	2.42e-05	5.08e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CA—melanoma	2.23e-05	4.67e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—melanoma	2.18e-05	4.56e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—melanoma	2.15e-05	4.51e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRAS—melanoma	2.06e-05	4.32e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—melanoma	1.97e-05	4.13e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—melanoma	1.82e-05	3.81e-05	CbGpPWpGaD
